Bookmark

Add to MyYahoo RSS

BioCryst Pharmaceuticals News

News on BioCryst Pharmaceuticals (Ticker: BCRX) continually updated from thousands of sources around the net.

20 hrs ago | Forbes.com

Use Options For a Chance To Buy BCRX at a 59% Discount

Options For Income is a contributor page created by the editors of Stock Options Channel, a stock options research Website.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets

Fri Aug 22, 2014

AmericanBankingNews.com

BioCryst Pharmaceuticals Receives Consensus Rating of "Buy" from Analysts

BioCryst Pharmaceuticals has earned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Stock Ratings Network reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Aug 19, 2014

Local Tech Wire

$4.1M federal grant could put BioCryst in Ebola fight - next time

It was not only a $4.1 million influx of additional federal research money to Durham drug development company BioCryst Pharmaceuticals.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, North Carolina, Epidemic, Natural Disasters

Mon Aug 18, 2014

AmericanBankingNews.com

BioCryst Pharmaceuticals Given Average Rating of "Buy" by Analysts

BioCryst Pharmaceuticals has received a consensus rating of "Buy" from the twelve analysts that are covering the stock, Stock Ratings Network reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Business Journal

Duke: Using experimental drug in Ebola outbreak could 'prove disastrous'

It's a debate federal regulators and drug companies have all the time. Should a company with an experimental drug give it to people in need to potentially save their lives, or should regulators make sure the drug is safe before it does any more harm? It's a question that seems to always result in a lose-lose situation.

Comment?

Related Topix: Medicine, Biotech, GlaxoSmithKline, Healthcare Industry

Thu Aug 14, 2014

Business Journal

Duke: Using experimental drug in Ebola outbreak could 'prove disastrous'

It's a debate federal regulators and drug companies have all the time. Should a company with an experimental drug give it to people in need to potentially save their lives, or should regulators make sure the drug is safe before it does any more harm? It's a question that seems to always result in a lose-lose situation.

Comment?

Related Topix: Medicine, Biotech, GlaxoSmithKline, Healthcare Industry

Wed Aug 13, 2014

BioSpace

Biocryst Pharmaceuticals Receives Additional National Institute of...

BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has exercised additional options to conduct Phase 1 clinical human safety trials of an intramuscular formulation of BCX4430, as well as efficacy studies in non-human primates to assess effective dose ranges and dose schedules.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Infectious Diseases, National Institutes of Health, Epidemic, Natural Disasters

Local Tech Wire

RTP drug firm BioCryst receives $4.1M in federal funds for Ebola vaccine

The U.S. government is stepping up efforts to find a successful treatment for Ebola with more funding going to a Triangle company.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Infectious Diseases

Tue Aug 12, 2014

Silicon Alley Insider

The Red-Hot Ebola Drug Stock Tekmira Is Down 20%

Ward physician Thomas Klotzkowski cleans doctor for tropical medicine, Florian Steiner, in a disinfection chamber at the quarantine station for patients with infectious diseases at the Charite hospital in Berlin August 11, 2014.

Comment?

Related Topix: Infectious Diseases, Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, Biotech, Healthcare Industry

Sat Aug 09, 2014

AmericanBankingNews.com

BioCryst Pharmaceuticals Coverage Initiated at JPMorgan Chase & Co.

The firm set an "overweight" rating and a $20.00 price target on the stock. JPMorgan Chase & Co.'

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Banking, JP Morgan Chase

Fri Aug 08, 2014

The Star Online

As virus spreads, investors bet on potential Ebola cures

Investors are showering attention on drug developers working on a potential treatment for the Ebola virus, even if some of the drugs are a long way from production.

Comment?

Related Topix: Epidemic, Natural Disasters, Biotech, Medicine, Healthcare Industry

TheStreet.com

Will This Coverage Initiation Help BioCryst Pharmaceuticals (BCRX) Stock Today?

The firm made the decision "based on both the near- and long-term potential of the company's unique, orally administered drug candidates for the prophylactic treatment of hereditary angioedema , a severely debilitating and potentially lethal orphan genetic disease," according to its research note issued Friday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, TheStreet, Genetics, Business News

Thu Aug 07, 2014

Business Journal

Durham's BioCryst to test potential Ebola drug in early 2015

In an attempt to bring out a treatment for Ebola, Durham drug developer BioCryst Pharmaceuticals plans to test a new drug in humans early next year.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Infectious Diseases

Tue Aug 05, 2014

BioSpace

Biocryst Pharmaceuticals Reports Second Quarter 2014 Financial Results

"The successful OPuS-1 Phase 2 clinical trial of BCX4161 in patients with hereditary angioedema established proof of concept for prophylaxis with an oral kallikrein inhibitor.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Infectious Diseases

Mon Aug 04, 2014

Business Journal

Durham's BioCryst sees stock increase 80% after Ebola outbreak

As a new Ebola outbreak ripples through Africa and takes up space on American front pages, investors have again - quietly - put some money in a Durham drug developer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Infectious Diseases

SchaeffersResearch.com

Stocks On the Move: BioCryst Pharmaceuticals, Inc., ITT Educational Services, Inc., and Pike Corp

Among the names making notable moves are drug maker BioCryst Pharmaceuticals, Inc. , for-profit education issue ITT Educational Services, Inc. , and construction concern Pike Corp .

Comment?

Related Topix: Biotech, Medicine, ITT Educational Services, Healthcare Industry, Education, Financial Markets, Day Trading, Personal Finance

AmericanBankingNews.com

BioCryst Pharmaceuticals (BCRX) to Release Earnings on Tuesday

BioCryst Pharmaceuticals will be posting its Q214 quarterly earnings results on Tuesday, August 5th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••